t
| Date | 28 Nov 2022 |
| Time | 07:00:09 |
| Category | AGMs and other meetings |
| ID | 7497H |
MGC Pharmaceuticals Ltd.
Results of AGM and Investor Presentation
28 November 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of plant inspired medicines, wishes to announce the results of the voting on resolutions put to the Company's shareholders at its 2022 Annual General Meeting, held on 24 November 2022.
The Company advises that all resolutions put to the meeting were decided on a poll, with the results of voting detailed in the table found at the following URL:
https://www.asx.com.au/asxpdf/20221125/pdf/45j1cnz2s7cpft.pdf
A copy of the Company's latest Investor Presentation can be found at the following URL:
https://www.asx.com.au/asxpdf/20221125/pdf/45j18gr4r19c73.pdf
--Ends--
Authorised for release by the Company Secretary, for further information please contact:
|
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 |
MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 |
|
UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 7810 056 104 |
UK Broker Turner Pope Andy Thacker +44 203 657 0050 |
|
UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150
|
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma